Tucatinib, palbociclib, and letrozole in HR+/HER2+metastatic breast cancer: Report of phase IB safety cohort.

被引：11
|
作者：
Shagisultanova, Elena
Chalasani, Pavani
Brown-Glaberman, Ursa Abigail
Gradishar, William John
Brenner, Andrew Jacob
Stopeck, Alison
Gao, Dexiang
McSpadden, Tessa
Kabos, Peter
Borges, Virginia F.
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Univ Arizona, Ctr Canc, Tucson, AZ USA
[3] UNM, Ctr Canc, Albuquerque, NM USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[5] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[6] Stony Brook Canc Ctr, Stony Brook, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1029
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
    Luis Fein
    Nicolas Lazaretti
    Yamil López Chuken
    J. Rogelio González Ramírez Benfield
    Max S. Mano
    Jose Lobaton
    Ernesto Korbenfeld
    Fernanda Damian
    Dongrui R. Lu
    Ave Mori
    Shem J. Patyna
    Sandra Franco
    Clinical Drug Investigation, 2023, 43 : 699 - 706
  • [42] Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2-Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
    Fein, Luis
    Lazaretti, Nicolas
    Chuken, Yamil Lopez
    Benfield, J. Rogelio Gonzalez Ramirez
    Mano, Max S. S.
    Lobaton, Jose
    Korbenfeld, Ernesto
    Damian, Fernanda
    Lu, Dongrui R. R.
    Mori, Ave
    Patyna, Shem J. J.
    Franco, Sandra
    CLINICAL DRUG INVESTIGATION, 2023, 43 (09) : 699 - 706
  • [43] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [44] Real-world patient characteristics and treatment patterns in HR+/HER2+metastatic breast cancer patients in 5 European countries
    Criscitiello, C.
    Lewis, K.
    Lambert, A.
    Thomason, G.
    Broughton, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S362 - S363
  • [45] HR+/HER2-locally advanced or metastatic Breast Cancer 5-Year Data underline the Efficacy of Palbociclib (IBRANCE®) in Combination with Letrozole in First-line Treatment
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (06)
  • [46] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [47] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
    Mitra, D.
    Darden, C.
    McSorley, D.
    Davis, K.
    Band, J.
    Iyer, S.
    VALUE IN HEALTH, 2018, 21 : S36 - S36
  • [48] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer
    Rugo, Hope S.
    Brufsky, Adam
    Liu, Xianchen
    Li, Benjamin
    McRoy, Lynn
    Chen, Connie
    Layman, Rachel M.
    Cristofanilli, Massimo
    Torres, Mylin A.
    Curigliano, Giuseppe
    Finn, Richard S.
    DeMichele, Angela
    NPJ BREAST CANCER, 2022, 8 (01)
  • [49] Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2-Advanced or Metastatic Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (01): : 6 - 15
  • [50] registHER: An observational cohort study of patients with HER2+metastatic breast cancer
    Yood, Marianne Ulcickas
    Kaufman, Peter A.
    Mayer, Musa
    Rugo, Hope
    Brufsky, Adam
    Tan-Chiu, Elizabeth
    Yardley, Denise
    Paik, Soonmyung
    Wang, Lisa
    Birkner, Merrill
    Brammer, Melissa
    Tripathy, Debu
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S40 - S40
12345